Fhoffmann La Roche competitive analysis

Explore patent oppositions filed by Fhoffmann La Roche against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jul 2, 2026
Patent NumberTitleApplicantOpposition Date
Antibodies And Fragments Thereof Raised Against The Alpha-3 Domain Of Hla-G Protein, Methods And Means For Their Preparation, And Uses ThereofINVECTYSOct 8, 2020
Modulation Of Ube3A-Ats ExpressionBAYLOR COLLEGE OF MEDICINEMay 14, 2019
Immunotherapeutic Molecules And UsesTHE UNIVERSITY OF BIRMINGHAMApr 23, 2019
Methods Of Preventing And Removing Trisulfide BondsBIOGEN IDEC MAJan 4, 2019
Use Of Perfusion To Enhance Production Of Fed-Batch Cell Culture In BioreactorsWYETHSep 19, 2018
Dual Antigen-Induced Bipartite Functional ComplementationJULIUS MAXIMILIANS UNIVERSITT WRZBURGJul 4, 2018
Purification Process For Monoclonal AntibodiesCADILA HEALTHCAREJun 12, 2018
Mammalian Cell Culture Processes For Protein ProductionBRISTOL MYERS SQUIBBFeb 27, 2018
Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsAMGENDec 1, 2017

Latest PTAB cases involving Fhoffmann La Roche

Discover the latest PTAB cases involving Fhoffmann La Roche, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Fhoffmann La Roche with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jul 2, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
FHOFFMANN LA ROCHE9 - - -
AMGEN8151811
AMGEN RESEARCH MUNICH - 32 - -
BAYLOR COLLEGE OF MEDICINE - 102 -